TVT study: 3-year results announced

Article

Three-year results from the Tube versus Trabeculectomy Study showed that tube-shunt surgery was more likely than trabeculectomy with mitomycin C to maintain IOP control and avoid persistent hypotony, loss of light perception vision, or re-operation for glaucoma.

Three-year results from the Tube versus Trabeculectomy Study showed that tube-shunt surgery was more likely than trabeculectomy with mitomycin C to maintain IOP control and avoid persistent hypotony, loss of light perception vision, or re-operation for glaucoma. A highly significant difference between study arms was apparent in the cumulative probability of failure analysis.

The cumulative probability of failure was estimated at 15.1% in the tube group and 30.7% in the trabeculectomy group at three years. The three-year analysis showed that most patients in both groups failed because of inadequate pressure control.

The treatment benefit for tube-shunt surgery was observed despite the findings of no significant difference between study groups in mean IOP and the mean number of glaucoma medications used at the three-year time point.

Visual acuity results in both study groups showed a reduction over the three-year period, and Snellen and Early-Treatment Diabetic Retinopathy Study acuity were similar for both sets of patients.

Although the findings do not demonstrate clear superiority of one glaucoma operation over the other, it was suggested that the role of tube shunts be expanded.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.